canertinib has been researched along with Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Abouzid, KAM; Lasheen, DS; Milik, SN; Serya, RAT | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Das, D; Hong, J | 1 |
| Bansal, R; Malhotra, A | 1 |
| Al-Nedawi, K; Garnier, D; Guha, A; Lee, TH; Lee, WJ; Meehan, B; Montermini, L; Rak, J | 1 |
| Crews, CM; Salami, J | 1 |
| Milsom, C; Rak, J; Xing, R; Yu, JL | 1 |
| Grünwald, V; Hidalgo, M | 1 |
| Allen, LF; Eiseman, IA; Fry, DW; Lenehan, PF | 1 |
| Galmarini, CM | 1 |
| Chayama, K; Kuwahara, K; Miyata, H; Murakami, M; Sasaki, T; Yamasaki, S | 1 |
| Dewji, MR | 1 |
| Bycott, P; Cunningham, C; Eiseman, I; Lenehan, PF; Nemunaitis, J; Olson, SC; Schlicht, M; Senzer, N; Shin, DM; Williams, A; Zentgraff, R; Zinner, RG | 1 |
| Atteridge, CE; Biggs, WH; Carter, TA; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Grotzfeld, RM; Herrgard, S; Insko, DE; Lockhart, DJ; Mehta, SA; Milanov, ZV; Pao, W; Patel, HK; Sawyers, CL; Shah, NP; Treiber, DK; Varmus, H; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Brose, MS; Flaherty, KT | 1 |
| Arun, BK; Eder, JP; Eiseman, IA; Garland, LL; Hidalgo, M; Lenehan, PF; Lovalvo, JL; Mendelson, DS; Olson, SC; Ryan, DP | 1 |
| Bepler, G; Chiappori, A; Daud, A; Eiseman, IA; Fishman, M; Garrett, CR; Langevin, M; Lenehan, PF; Lush, R; Mahany, JJ; Munster, P; Olson, SC; Simon, GR; Sullivan, DM; Williams, CC | 1 |
| Christensen, J; Donato, NJ; Eiseman, I; Huang, X; Lenehan, PF; Nemunaitis, J; Olson, SC; Shin, DM; Shin, HJ; Zinner, RG | 1 |
| Alroy, I; Citri, A; Fry, DW; Grammatikakis, N; Lavi, S; Neckers, L; Patterson, C; Rubin, C; Xu, W; Yarden, Y | 1 |
11 review(s) available for canertinib and Neoplasms
| Article | Year |
|---|---|
How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Humans; Models, Molecular; Neoplasms; Point Mutation; Protein Domains; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2017 |
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
Waste disposal-An attractive strategy for cancer therapy.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Humans; Molecular Targeted Therapy; Morpholines; Neoplasms; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Proteolysis; Small Molecule Libraries; Ubiquitin | 2017 |
Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Factor VIIa; Genes, ras; Humans; Mice; Mice, SCID; Morpholines; Neoplasms; Oncogenes; Phosphotransferases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thromboplastin; Trastuzumab; Tyrphostins; Up-Regulation | 2010 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Ligands; Morpholines; Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2003 |
Canertinib pfizer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Humans; Morpholines; Neoplasms; Structure-Activity Relationship | 2004 |
Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?
Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Biological Availability; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Morpholines; Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2004 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
4 trial(s) available for canertinib and Neoplasms
| Article | Year |
|---|---|
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Diarrhea; Drug Administration Schedule; Exanthema; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Protein-Tyrosine Kinases | 2005 |
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Chemical; Morpholines; Neoplasms; Neutropenia; Taxoids | 2006 |
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Predictive Value of Tests; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome | 2006 |
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Morpholines; Neoplasms | 2007 |
4 other study(ies) available for canertinib and Neoplasms
| Article | Year |
|---|---|
Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content.
Topics: Animals; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Cetuximab; Culture Media, Conditioned; DNA; ErbB Receptors; Etoposide; Exosomes; Extracellular Vesicles; Glioma; Humans; Mice; Mice, SCID; Morpholines; Neoplasm Transplantation; Neoplasms; Phosphoproteins; Phosphorylation; Proteomics; Quinazolinones; Transfection | 2015 |
Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT-1 cells.
Topics: Apoptosis; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Carrier Proteins; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; ErbB Receptors; Fas Ligand Protein; fas Receptor; Flow Cytometry; Humans; Immunohistochemistry; Membrane Glycoproteins; Morpholines; Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Radiation, Ionizing | 2004 |
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Topics: Aminoquinolines; Aniline Compounds; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kinetics; Morpholines; Mutation; Naphthalenes; Neoplasms; Oncogene Proteins v-abl; Organic Chemicals; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Sunitinib | 2005 |
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.
Topics: Antineoplastic Agents; Benzoquinones; Cell Division; Cell Line; Endocytosis; Enzyme Inhibitors; Humans; Lactams, Macrocyclic; Morpholines; Neoplasms; Protein-Tyrosine Kinases; Quinones; Receptor, ErbB-2; Recombinant Proteins; Transfection; Ubiquitin | 2002 |